Physician profile
Leslie Feigin
NPI 1447336250
$6,555.60
in general payments reported to CMS, 2019-2025
49 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,218 · 2020: $1,451 · 2021: $1,808 · 2022: $1,079.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,225.92 | 2019-2022 | |
| Amgen INC. | $636.30 | 2019-2022 | |
| Abbvie INC. | $626.89 | 2020-2022 | |
| Allergan, INC. | $623.61 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $555.04 | 2019-2022 | |
| Lilly USA, LLC | $371.83 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $218.58 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $217.73 | 2019-2022 | |
| Abbott Laboratories | $203.01 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.28 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.81 | 2019-2022 | |
| Ibsa Pharma INC. | $118.38 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $111.09 | 2019-2021 | |
| Glaxosmithkline, LLC. | $97.80 | 2020-2022 | |
| Amarin Pharma, INC. | $85.54 | 2019-2021 |
Show all 49 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Feigin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.